S, L., X, X., X, Y., X, Z., C, W., D, C., . . . J, H. (2020). Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS. Dove Medical Press.
Chicago Style (17th ed.) CitationS, Luo, et al. Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS. Dove Medical Press, 2020.
MLA (8th ed.) CitationS, Luo, et al. Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS. Dove Medical Press, 2020.
Warning: These citations may not always be 100% accurate.